Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

What It Covers

Heather Turner, CEO of LB Pharmaceuticals, traces her path from environmental law to biotech executive, culminating in Carmot Therapeutics' $2.7B Roche acquisition. She now leads LB Pharmaceuticals through late-stage development of LB102, a methylated amisulpride derivative targeting schizophrenia, bipolar depression, and adjunctive major depressive disorder.

Key Questions Answered

• •Blood-brain barrier modification: Adding a single methyl group to amisulpride transforms a 50-country-approved antipsychotic into a once-daily compound with improved brain penetration. The methylation increases lipophilicity, enabling more efficient transport across the blood-brain barrier, reducing required doses, extending brain residence time, and opening a long-acting injectable formulation pathway — a meaningful adherence advantage in schizophrenia where staying on medication is the central clinical challenge.
• •Placebo rate management in CNS trials: Unlike metabolic trials where outcomes are objective measurements like body weight, neuropsychiatric trials rely on subjective symptom scales, making placebo response rates a primary execution risk. LB102's Phase 2 NOVA-1 trial achieved statistical significance across all three doses (50mg, 75mg, 100mg) partly by actively managing placebo inflation — a trial design discipline that Turner identifies as underappreciated before entering the CNS space.
• •Cognition as a cross-indication signal: LB102's Phase 2 data showed a measurable effect on cognitive impairment, a symptom affecting roughly 80% of schizophrenia patients and 45–60% of bipolar and MDD patients. This cognitive signal creates a clinical rationale for expanding into mood disorders beyond schizophrenia, and Turner plans to formally assess cognition endpoints across all subsequent trials as a differentiating data point.
• •Recap IPO as a price-discovery tool: Facing $14M in remaining cash, no crossover round, and a two-year timeline to catalyst, LB Pharmaceuticals executed an IPO by inverting the standard pricing dynamic — asking investors what they would pay rather than dictating terms. This approach self-selected for long-duration investors comfortable with a two-year wait, producing post-IPO price stability and enabling a subsequent $100M PIPE within months of listing.
• •General counsel as CEO training ground: The GC role provides exposure to every company function — finance, HR, regulatory, strategy, board governance — through contract review, risk assessment, and large project management like IPOs and M&A. Turner argues this breadth, combined with managing high-stakes litigation and capital transactions, builds the operational range needed for a CEO role faster than most functional career paths, particularly for business-minded attorneys in biotech.
• •End-of-phase-two FDA meeting as a financing lever: LB Pharmaceuticals' FDA end-of-phase-two meeting produced feedback indicating the Phase 2 trial had characteristics of an adequate and well-controlled study, suggesting a single successful Phase 3 trial could support an NDA submission. This regulatory signal directly enabled the company's fundraising narrative, justifying the capital required for a full Phase 3 schizophrenia program rather than a more modest Phase 2 repeat.